Dodecanol

Dodecanol

SCHEMBL3406388

CCCCCCCCCCCCN(CCCCCCCCCCCC)CCCCCCCCCCCC.CCCCCCCCCCCCO

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.68
ALDH1A1 P00352 2/20 0.68
TSHR P16473 2/20 0.68
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
HSD17B10 Q99714 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.63
DNM1 Q05193 4/20 0.48
KDM5A P29375 2/20 0.43
PHF8 Q9UPP1 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
THRB P10828 2/20 0.42
GBA1 P04062 1/20 0.40
ICMT O60725 1/20 0.40
ALB P02768 1/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1404085 1.00 LMNA (0.68) LMNAALDH1A1TSHRMEN1KMT2A
SCHEMBL1262955 1.00 LMNA (0.68) LMNAALDH1A1TSHRMEN1KMT2A
SCHEMBL1404155 1.00 LMNA (0.68) LMNAALDH1A1TSHRMEN1KMT2A
SCHEMBL9807808 1.00 LMNA (0.68) LMNAALDH1A1TSHRMEN1KMT2A
SCHEMBL1404090 1.00 LMNA (0.68) LMNAALDH1A1TSHRMEN1KMT2A
SCHEMBL23888725 1.00 LMNA (0.68) LMNAALDH1A1TSHRMEN1KMT2A
Octanol SCHEMBL11125952 1.00 LMNA (0.68) LMNAALDH1A1TSHRMEN1KMT2A
SCHEMBL4937294 1.00 LMNA (0.68) LMNAALDH1A1TSHRMEN1KMT2A
Octanol SCHEMBL22656886 1.00 LMNA (0.68) LMNAALDH1A1TSHRMEN1KMT2A
SCHEMBL8053580 1.00 LMNA (0.68) LMNAALDH1A1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476424-B2 Removal of acids from tertiary amide solvents TATE & LYLE TECHNOLOGY LIMITED (GB) 2013-07-02 US disclosed
EP-2254677-A1 REMOVAL OF ACIDS FROM TERTIARY AMIDE SOLVENTS Tate & Lyle Technology Limited (GB) 2010-12-01 EP disclosed
US-20090259034-A1 REMOVAL OF ACIDS FROM TERTIARY AMIDE SOLVENTS TATE & LYLE TECHNOLOGY LIMITED (GB) 2009-10-15 US disclosed
WO-2009117317-A1 REMOVAL OF ACIDS FROM TERTIARY AMIDE SOLVENTS TATE & LYLE TECHNOLOGY LTD (GB) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090259034-A1 REMOVAL OF ACIDS FROM TERTIARY AMIDE SOLVENTS ACMSD, NAAA, ABHD6 LMNA 3638/4885ALDH1A1 673/4885TSHR 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.